tirzepatide fda approval date Breaking News: Approves For Treating Obesity FDA Grants Tirzepatide a New

Anti-atherosclerotic effects of geraniin through the gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway in mice

Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial

SELECT (CV outcomes): The landmark 17,604-patient trial demonstrating 20% MACE reduction in overweight/obese adults with established CVD but without diabetes -- establishing semaglutide as the first anti-obesity medication with proven cardiovascular benefit

(accessed Aug 21, 2013)

If you are losing weight quickly, ask your clinician whether the pace and plan are appropriate

A more evidence-based way to evaluate whether something is helping is to track measurable outcomes with your clinician (for example, symptoms tied to confirmed deficiency, or objective metrics like body weight, waist measurements, and lab work when appropriate)